Literature DB >> 19590832

[Neuromuscular monitoring in patients with neuromuscular diseases. Options and needs].

A Beloiartsev1, S Gableske, M Hübler.   

Abstract

The management of general anaesthesia in patients with neuromuscular disorders remains challenging. The underlying causes and clinical presentations of these rare heterogeneous diseases are highly variable and the only common feature is usually skeletal muscle weakness. The appropriate choice and dosage of muscle relaxants are important and an adequate monitoring of the neuromuscular blockade is obligatory. Neuromuscular monitoring can be complicated because of disease-induced alterations in neurophysiology; however, continuous monitoring of the neuromuscular blockade should be realized to accurately determine the recovery from the blockade. These patients very often have an increased risk for postoperative pulmonary complications, which increases further if a residual neuromuscular blockade is present.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590832     DOI: 10.1007/s00101-009-1578-0

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  37 in total

1.  Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients.

Authors:  R Mann; M Blobner; S Jelen-Esselborn; R Busley; C Werner
Journal:  Anesthesiology       Date:  2000-08       Impact factor: 7.892

2.  Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action.

Authors:  Bertrand Debaene; Benoît Plaud; Marie-Pierre Dilly; François Donati
Journal:  Anesthesiology       Date:  2003-05       Impact factor: 7.892

3.  Does repetition of post-tetanic count every 3 min during profound relaxation affect accelerographic recovery of atracurium blockade?

Authors:  C Motamed; K Kirov; X Combes; P Duvaldestin
Journal:  Acta Anaesthesiol Scand       Date:  2005-07       Impact factor: 2.105

4.  Sensitivity to curare in patients with upper and lower motor neurone dysfunction.

Authors:  F Fiacchino; M Gemma; M Bricchi; S Giombini; B Regi
Journal:  Anaesthesia       Date:  1991-11       Impact factor: 6.955

5.  [Anesthetic complications. The incidence of severe anesthetic complications in patients and families with progressive muscular dystrophy of the Duchenne and Becker types].

Authors:  E Breucking; P Reimnitz; U Schara; W Mortier
Journal:  Anaesthesist       Date:  2000-03       Impact factor: 1.041

6.  Rocuronium for muscle relaxation in two children with Friedreich's ataxia.

Authors:  H J Schmitt; S Wick; T Münster
Journal:  Br J Anaesth       Date:  2004-02-20       Impact factor: 9.166

7.  Cough dynamics during progressive expiratory muscle weakness in healthy curarized subjects.

Authors:  N S Arora; T J Gal
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1981-08

8.  Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers.

Authors:  L I Eriksson; E Sundman; R Olsson; L Nilsson; H Witt; O Ekberg; R Kuylenstierna
Journal:  Anesthesiology       Date:  1997-11       Impact factor: 7.892

9.  [Failure of relaxometry in diabetic polyneuropathy].

Authors:  D Knüttgen; D Bremerich; J Rings; A Curth; M Doehn
Journal:  Anaesthesist       Date:  1992-09       Impact factor: 1.041

Review 10.  Anesthesia issues in the perioperative management of myasthenia gravis.

Authors:  Francis X Dillon
Journal:  Semin Neurol       Date:  2004-03       Impact factor: 3.420

View more
  2 in total

1.  [Anesthesia with neuromuscular diseases].

Authors:  M U Gerbershagen; F Wappler
Journal:  Anaesthesist       Date:  2010-10       Impact factor: 1.041

2.  Spinal anesthesia for cesarean section in a patient with chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Torsten Richter; Karl-Anton Langer; Thea Koch
Journal:  J Anesth       Date:  2011-12-17       Impact factor: 2.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.